Physician
Rainbow Pediatrics of Fayetteville
Rainbow Pediatrics of Fayetteville was paid $21.24M by Medicaid between Jan 2018 and Dec 2024, across 82 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 29% of everything it billed.
33Billing provider infoRAINBOW PEDIATRICS OF FAYETTEVILLE
FAYETTEVILLE, NC 28305
FAYETTEVILLE, NC 28305
33aNPI1356439566assigned 10/11/2006
33bProvider typePediatrics Physician
28Total paid$21.24M
24GClaims1,189,775
24DCodes billed82
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in North Carolina
Rank by total paid#7 of 433
Median peer was paid$942K
This provider vs. median23×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 74,957 | $2.10M | |
| 2019 | 74,626 | $2.37M | |
| 2020 | 65,116 | $2.11M | |
| 2021 | 156,974 | $3.04M | |
| 2022 | 289,704 | $4.43M | |
| 2023 | 272,343 | $3.93M | |
| 2024incomplete | 256,055 | $3.26M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 29% | 70,287 | 59,258 | $6.10M |
| 99199 | Unlisted special service, procedure or report | 18% | 635,478 | 384,247 | $3.72M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 43,398 | 37,769 | $2.50M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 7.5% | 42,674 | 38,492 | $1.59M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 6.5% | 15,875 | 14,294 | $1.39M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 5.7% | 14,290 | 12,665 | $1.20M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.4% | 13,184 | 11,912 | $1.16M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.0% | 10,557 | 9,198 | $630K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.6% | 11,641 | 8,835 | $545K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.7% | 3,766 | 3,484 | $361K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.1% | 24,515 | 22,118 | $244K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 23,952 | 21,433 | $213K |
70 more codes
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 16,106 | $210K |
| 96127 | <1% | 26,312 | $178K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,065 | $162K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 538 | $127K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,150 | $104K |
| D0145 | Oral evaluation for a patient under three years of age | <1% | 3,149 | $102K |
| 99460 | <1% | 1,387 | $99K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,450 | $89K |
| 99051 | <1% | 3,054 | $74K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 627 | $74K |
| D1206 | Topical application of fluoride varnish | <1% | 3,152 | $45K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,123 | $39K |
| 87634 | <1% | 1,043 | $29K | |
| 99462 | <1% | 827 | $27K | |
| 96161 | <1% | 5,440 | $19K | |
| 0072A | <1% | 326 | $16K | |
| 0071A | <1% | 311 | $15K | |
| 87631 | <1% | 176 | $14K | |
| 0001A | <1% | 257 | $13K | |
| 0002A | <1% | 253 | $13K | |
| 90461 | <1% | 20,162 | $12K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 842 | $12K |
| 88738 | <1% | 1,966 | $11K | |
| 90651 | <1% | 460 | $11K | |
| 92558 | <1% | 22,005 | $10K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 74 | $9K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 906 | $8K |
| 90686 | <1% | 9,325 | $7K | |
| 94760 | <1% | 48,217 | $7K | |
| 99177 | <1% | 36,327 | $6K | |
| 99417 | Prolong home eval add 15m | <1% | 35 | $6K |
| 94664 | <1% | 553 | $6K | |
| 80061 | Lipid panel | <1% | 285 | $4K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 223 | $4K |
| G9919 | Screening performed and positive and provision of recommendations | <1% | 99 | $3K |
| 99383 | <1% | 25 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 43 | $2K |
| 94010 | <1% | 70 | $2K | |
| 90734 | <1% | 90 | $1K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 41 | $1K |
| 0081A | <1% | 19 | $1K | |
| 90620 | <1% | 104 | $812.73 | |
| 85018 | <1% | 1,517 | $655.63 | |
| 92567 | <1% | 38 | $456.60 | |
| 90619 | <1% | 130 | $171.22 | |
| 90633 | <1% | 1,764 | $170.17 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 620 | $132.27 |
| 90656 | <1% | 818 | $102.66 | |
| 36416 | <1% | 25,064 | $80.02 | |
| 90744 | <1% | 2,162 | $74.86 | |
| 82962 | <1% | 12 | $35.57 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 81 | $10.48 |
| 99072 | <1% | 6,938 | $0.34 | |
| 90680 | 0% | 4,313 | $0.00 | |
| 90698 | 0% | 5,213 | $0.00 | |
| 99000 | 0% | 1,614 | $0.00 | |
| 90647 | 0% | 129 | $0.00 | |
| 90716 | 0% | 156 | $0.00 | |
| 91307 | 0% | 688 | $0.00 | |
| 90696 | 0% | 64 | $0.00 | |
| 90677 | 0% | 65 | $0.00 | |
| J7609 | Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mg | 0% | 87 | $0.00 |
| 90670 | 0% | 9,030 | $0.00 | |
| 91300 | 0% | 624 | $0.00 | |
| 90707 | 0% | 156 | $0.00 | |
| 90685 | 0% | 43 | $0.00 | |
| 90700 | 0% | 108 | $0.00 | |
| 90710 | 0% | 61 | $0.00 | |
| 91308 | 0% | 34 | $0.00 | |
| 90715 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialESENSOY, TANER (PRESIDENT)